Key player in Pershing Square's Valeant bet leaving firm

Wed May 11, 2016 4:21pm EDT
 
Email This Article |
Share This Article
  • Facebook
  • LinkedIn
  • Twitter
| Print This Article
[-] Text [+]

LAS VEGAS May 11 (Reuters) - William Doyle, a key figure in Pershing Square Capital Management's controversial investment in battered drug company Valeant Pharmaceuticals, is leaving the hedge fund, its founder, William Ackman, told investors on Wednesday. (Reporting by Svea Herbst-Bayliss; Editing by Chris Reese)